Osaic Holdings’s CytoMed Therapeutics GDTC Stock Holding History

Osaic Holdings’s Portfolio GDTC Stock Details GDTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21	Hold	21	–	–	﹤0.01%	7920
2026 Q1	$21	Hold	21	–	–	﹤0.01%	7719
2025 Q4	$28	Buy	+21	New	+$41	﹤0.01%	7723

Other funds holding GDTC

AIM

Axiom Investment Management New York $150M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings's GDTC Position: Q2 2026 in Review

Osaic Holdings held its CytoMed Therapeutics (GDTC) position steady in Q2 2026 at 21 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #7920.

Osaic Holdings first reported a position in GDTC in Q4 2025 and has held it in 3 quarters since. The position peaked at $28 in Q4 2025. 3 funds tracked by Wall St. Rank hold GDTC as of Q2 2026.

Osaic Holdings held 21 shares of CytoMed Therapeutics worth $21 as of Q2 2026.
Osaic Holdings left its CytoMed Therapeutics share count unchanged in Q2 2026.
CytoMed Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7920 holding.
Osaic Holdings first reported a position in CytoMed Therapeutics in Q4 2025 and has held it in 3 quarters since.
Osaic Holdings's CytoMed Therapeutics position peaked at $28 in Q4 2025.
3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.